Open AccessThalidomide in Advanced Hepatocellular Carcinoma with Optional Low‐Dose Interferon‐α2a upon Progression
Author(s) -
Schwartz Jonathan D.,
Sung Max,
Schwartz Myron,
Lehrer Deborah,
Mandeli John,
Liebes Leonard,
Goldenberg Alec,
Volm Matthew
Publication year - 2005
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.10-9-718
Subject(s) - medicine , hepatocellular carcinoma , thalidomide , tumor progression , oncology , gastroenterology , metastasis , cirrhosis , sorafenib , cancer , multiple myeloma
L earning O bjectives After completing this course, the reader will be able to: Identify the etiologic factors contributing to the increasing incidence of hepatocellular carcinoma in the U.S. Explain the rationale for antiangiogenic therapeutic strategies in the treatment of hepatocellular carcinoma. Describe the clinical features associated with a particularly poor prognosis in unresectable hepatocellular carcinoma.Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com